We are pleased to announce that our Lab Testing Division’s late-and commercial-stage analytical and stability testing facilities in Shanghai successfully passed an FDA inspection for GMP compliance.   The inspector from FDA China office evaluated WuXi’s quality system during a 4-day inspection, with focus on data integrity and compliance across its GMP analytical and stability testing facilities. The inspection outcome confirmed WuXi’s adherence to FDA’s rigorous GMP guidance and its high quality of operation.  FDA expects the highest quality and data integrity, and we are proud to receive a very positive feedback.


Related Articles:

  1. WuXi’s STA Subsidiary Receives First Approval from Japanese Regulatory Authorities
  2. WuXi Facility Passes US FDA Inspection for Manufacture of API
  3. WuXi’s Toxicology Facility in Suzhou Passes OECD GLP Inspection